Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06813365RecruitingPhase 1
A targeted therapy for EGFR-mutated advanced lung cancer
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT06762405RecruitingPhase 3
Testing dostarlimab with short radiation for MSI rectal cancer
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
DijonAges 18 years+ - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for advanced lung cancer with bone metastases
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06718621RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+ - NCT06641609RecruitingPhase 1
Study of CFT8919 for advanced NSCLC with EGFR L858R mutation
This trial tests a new drug, CFT8919, for people with a specific type of advanced lung cancer (non-small cell lung cancer with an EGFR L858R mutation) that has stopped responding to other treatments. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06627738RecruitingPhase 2
Extra radiation boost for advanced lung cancer after standard treatment
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
NiceAges 18 years+ - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06607302Recruiting
Study of ivosidenib for bile duct cancer with IDH1 mutation
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
AugsburgAges 18 years+ - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT06587295RecruitingPhase 1
ACM-CpG injection for advanced solid tumors that responded to immunotherapy before
This trial tests a new injection, ACM-CpG, for people with advanced or metastatic solid tumors that previously responded to immunotherapy (with or without chemotherapy) but later grew again. The goal is to see if ACM-CpG can help when other treatments have stopped working.
SingaporeAges 21–99 - NCT06578624RecruitingPhase 1/Phase 2
SA53-OS for advanced solid tumors
This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.
Canton, OhioAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.